An autopsy case of aggressive CD30+ extra-nodal NK/T-cell lymphoma initially manifested with granulomatous myositis.

Abstract:

:This study reports an autopsy case of a 53 year-old male with rapidly progressive extra-nodal NK/T-cell lymphoma accompanied with unusual clinical and pathologic features. He was initially presented with localized swelling and tenderness in the right lower extremity and the biopsy from the calf muscle was interpreted as granulomatous myositis masquerizing lymphoma. The biopsy from erythematous skin lesion of trunk showed infiltration of medium sized atypical lymphoid cells with relatively plump cytoplasm and immunophenotype of CD30+, CD56+/- and surface CD3-, which lead to the diagnosis of CD30+ anaplastic large cell lymphoma. About 2 months later, nasal obstruction was developed and the nasal biopsy was done. After confirmation of EBV infection, he was finally diagnosed as extra-nodal NK/T-cell lymphoma with peculiar immunophenotype of CD3 dim+ and CD30+. Despite the chemotherapy, he was going rapidly downhill and died of respiratory and multi-organ failure 8 months after the onset of soft tissue lesion. At autopsy, disseminated angiocentric lymphoma was found all over the internal organs including the brain. This case emphasizes that extra-nodal NK/T-cell lymphoma should be considered as a cause of granulomatous myositis and can express CD30 positivity and CD3 weak positivity, which are unusual but rarely predominant feature of NK/T-cell lymphoma.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Min HS,Hyun CL,Paik JH,Jeon YK,Choi G,Park SH,Seo JW,Kim CW

doi

10.1080/10428190500288545

keywords:

subject

Has Abstract

pub_date

2006-02-01 00:00:00

pages

347-52

issue

2

eissn

1042-8194

issn

1029-2403

pii

V031774166307143

journal_volume

47

pub_type

杂志文章
  • The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.

    abstract::We examined the effect of high-dose methylprednisolone (HDMP) on blast reduction rate and compared it to conventional dose steroid treatment, administered during the first 7+ days of the induction remission period in patients with acute lymphoblastic leukemia (ALL). In our previous randomized study, the event free sur...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1080/1042819021000055048

    authors: Yetgin S,Cetin M

    更新日期:2003-03-01 00:00:00

  • Detection of simian virus 40 DNA sequences in Egyptian patients with different hematological malignancies.

    abstract::SV40 DNA sequences have been detected in non-Hodgkin's lymphoma patients. A link between SV40 and NHL is biologically plausible since SV40 causes hematological malignancies in laboratory rodents. We investigated 266 Egyptian cases of hematological malignancies (158 NHL, 54 HD, 26 ALL, 13 AML, 8 CLL, 7 CML) and 34 subj...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701534408

    authors: Zekri AR,Mohamed W,Bahnassy A,Refat L,Khaled M,Shalaby S,Hafez M

    更新日期:2007-09-01 00:00:00

  • Parvovirus-B19 infection preceding acute myeloid leukemia with orbital granulocytic sarcoma.

    abstract::We report here an unusual presentation of acute nonlymphoblastic leukemia with ocular granulocytic sarcoma who was firstly diagnosed iron deficiency anemia and acute parvovirus infection induced erythroid hypoplasia. To our knowledge this is the first paper of acute myeloblastic leukemia (AML) with granulocytic sarcom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000016168

    authors: Fisgin T,Yarali N,Duru F,Kara A

    更新日期:2002-10-01 00:00:00

  • The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.

    abstract::From July 1983 to January 1991 a total of 622 patients were randomized (585 eligible) to compare the effects of hydroxyurea, interferon alpha (IFN), and busulfan on the duration of chronic phase, and survival. Further goals included the determination of prognostic parameters. 598 CML patients were documented and 575 e...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428199309047880

    authors: Hehlmann R,Heimpel H,Kolb HJ,Heinze B,Hochhaus A,Griesshammer M,Pralle H,Queisser WP,Essers U,Falge C

    更新日期:1993-01-01 00:00:00

  • Secondary chromosome changes in mantle cell lymphoma: cytogenetic and fluorescence in situ hybridization studies.

    abstract::To better define the incidence and nature of secondary chromosome anomalies in mantle cell lymphoma (MCL) carrying the t(11:14)/BCL1 rearrangement, cytogenetic and fluorescence in situ hybridization studies (FISH) were performed in 42 patients (39 classical histology, 3 blastoid variant), using 6q21, 9p21/p16, 13q14, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097656

    authors: Bigoni R,Cuneo A,Milani R,Roberti MG,Bardi A,Rigolin GM,Cavazzini F,Agostini P,Castoldi G

    更新日期:2001-02-01 00:00:00

  • Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group.

    abstract::In this prospective, multicenter, non-randomized study for patients with stage I-II Hodgkin lymphoma, group 1 (without risk-factors [RF]) had three cycles of ABVD chemotherapy (adriamycin, bleomycin, vinblastine, and dacarbazine) and group 2 (any of bulk, extranodal site, >3 regions, raised erythrocyte sedimentation r...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428194.2010.547155

    authors: Wirth A,Grigg A,Wolf M,Goldstein D,Johnson C,Davis S,Dutu G,Kypreos P,Smith C,Kneebone A,Herzberg M,Joseph D,Catalano J,Roos D,Stone J,Reynolds J

    更新日期:2011-05-01 00:00:00

  • Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy.

    abstract::Abstract The aim of this study was to evaluate the prognostic importance of rituximab and radiotherapy in patients with primary mediastinal large B-cell lymphoma (PMBCL) receiving doxorubicin-containing chemotherapy. Seventy-nine patients with PMBCL received CHOP chemotherapy with (n = 39) or without rituximab (n = 40...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.746684

    authors: Xu LM,Fang H,Wang WH,Jin J,Wang SL,Liu YP,Song YW,Ren H,Zhou LQ,Li YX

    更新日期:2013-08-01 00:00:00

  • Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments.

    abstract::The occurrence of unexplained peripheral blood cytopenia, particularly neutropenia, has been recently reported after rituximab. Its prevalence may be underestimated since it may occur late after treatment. This study analysed all cases of unexplained delayed-onset peripheral blood cytopenia of WHO grade II - IV occurr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500473113

    authors: Cattaneo C,Spedini P,Casari S,Re A,Tucci A,Borlenghi E,Ungari M,Ruggeri G,Rossi G

    更新日期:2006-06-01 00:00:00

  • Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

    abstract::Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.803226

    authors: Brown JR

    更新日期:2014-02-01 00:00:00

  • Therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: possible use of interferon on the basis of some novel concepts.

    abstract::Current understanding of molecular genetics enables the establishment of new categories based on pathogenesis. Philadelphia (Ph) chromosome-positive leukemia has been reclassified into two molecularly distinct subsets, and the leukemogenesis at the cell level might be linked to the molecular changes. Therefore, treatm...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309148502

    authors: Ohyashiki K,Ohyashiki JH,Toyama K

    更新日期:1993-01-01 00:00:00

  • Clinical significance of detecting p53 protein in Burkitt lymphoma and B-cell acute lymphoblastic leukemia using immunocytochemistry.

    abstract::P53 protein expression in malignant cells of five patients with Burkitt lymphoma (BL) and from two patients with B-cell acute lymphoblastic leukemia (B-ALL) was examined with anti p53 protein monoclonal antibodies PAb1801, PAb240 and p53-D07 using an immunocytochemical technique. Four of the seven patients were positi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809058368

    authors: Nagai J,Kigasawa H,Koga N,Katoh A,Nishihira H,Nagao T

    更新日期:1998-02-01 00:00:00

  • Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.

    abstract::Elevated serum free light chains (FLCs) have been associated with an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). The aim of this study was to determine the clinical relevance of a quantitative assessment of intact circulating immunoglobulin (Ig), using serum Ig heavy chain/light chain pair (HLC) me...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.767456

    authors: Jardin F,Delfau-Larue MH,Molina TJ,Copie-Bergman C,Brière J,Petrella T,Canioni D,Fabiani B,Jais JP,Figeac M,Leroy K,Mareschal S,Salles GA,Coiffier B,Delarue R,Peyrade F,Bosly A,André M,Ketterer N,Haioun C,Tilly H

    更新日期:2013-09-01 00:00:00

  • Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.

    abstract::A recent phase III trial demonstrated improved progression-free survival (PFS) and overall survival (OS) associated with adding rituximab to fludarabine and cyclophosphamide (R-FC) compared to FC in treatment of previously untreated chronic lymphocytic leukemia (CLL). A cost-effectiveness analysis of R-FC over FC was ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,随机对照试验

    doi:10.3109/10428194.2011.605918

    authors: Hornberger J,Reyes C,Shewade A,Lerner S,Friedmann M,Han L,Gutierrez H,Satram-Hoang S,Keating MJ

    更新日期:2012-02-01 00:00:00

  • [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.

    abstract::Positron emission tomography (PET) after induction therapy in follicular lymphoma (FL) is predictive of survival in clinical trials. We describe use of PET and computed tomography (CT) after rituximab-based induction therapy in FL patients followed by the National LymphoCare Study and explore the association between i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1213824

    authors: Wong-Sefidan I,Byrtek M,Zhou X,Friedberg JW,Flowers CR,Zelenetz AD,Dawson KL,Reid E

    更新日期:2017-04-01 00:00:00

  • Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.

    abstract::Male gender was recently reported as an adverse prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). We conducted a retrospective study of adult patients with DLBCL initially treated with rituximab containin...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.691482

    authors: Carella AM,de Souza CA,Luminari S,Marcheselli L,Chiappella A,di Rocco A,Cesaretti M,Rossi A,Rigacci L,Gaidano G,Merli F,Spina M,Stelitano C,Hohaus S,Barbui A,Puccini B,Miranda EC,Guida A,Federico M

    更新日期:2013-01-01 00:00:00

  • Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOAG17V and IDH2R172 hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma.

    abstract::We applied two-step multicolor flow cytometry (FCM) for circulating lymphoma cells in the blood of 20 patients with angioimmunoblastic T-cell lymphoma (AITL) and confirmed neoplastic T-cells in all. Eleven exhibited dim expression of CD3 and 7 lost its expression. The proportion of CD10+ lymphoma cells ranged widely f...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1768382

    authors: Hayashida M,Maekawa F,Chagi Y,Iioka F,Kobashi Y,Watanabe M,Ohno H

    更新日期:2020-10-01 00:00:00

  • Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas.

    abstract::Bone marrow angiogenesis is increased in non-Hodgkin lymphomas (NHL). Compounds affecting extracellular matrix (ECM) may modify angiogenesis. Here we investigated ECM regulators in 48 unselected NHL patients compared with 35 controls. Untreated patients had elevated (P < 0.05) serum matrix metalloproteinase (MMP) 9 an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902889270

    authors: Negaard HF,Svennevig K,Kolset SO,Iversen N,Lothe IM,Østenstad B,Sandset PM,Iversen PO

    更新日期:2009-06-01 00:00:00

  • Bone marrow aplasia with prominent atypical plasmacytic proliferation preceding acute lymphoblastic leukemia.

    abstract::A two-year-old boy presented with pancytopenia. Bone marrow examination revealed an aplastic marrow with prominent immature plasma cell proliferation, which mimicked plasma cell leukemia. Immunohistochemistry, however, revealed a polyclonal population consistent with a reactive process, excluding plasma cell neoplasia...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909145722

    authors: Kikuchi M,Ohsaka A,Chiba Y,Sato M,Muraosa Y,Hoshino H

    更新日期:1999-09-01 00:00:00

  • Adhesion properties of adult T cell leukemia cells.

    abstract::The interaction between neoplastic as well as normal T cells and vascular endothelial cells which is mediated by adhesion molecules play a key role in their trafficking, localization and infiltration. This brief article reviews our studies on the expression of adhesion molecules on leukemic cells isolated from patient...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509054426

    authors: Uchiyama T,Ishikawa T,Imura A

    更新日期:1995-02-01 00:00:00

  • Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.

    abstract::PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-daily PTK787/ZK222584 at a target dose of 1250 mg. Eighteen patien...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.784969

    authors: Brander D,Rizzieri D,Gockerman J,Diehl L,Shea TC,Decastro C,Moore JO,Beaven A

    更新日期:2013-12-01 00:00:00

  • Post-transplantation lymphoproliferative disease in Chinese: the Queen Mary Hospital experience in Hong Kong.

    abstract::Post-transplantation lymphoproliferative disease (PTLD) is an unique iatrogenic complication after bone marrow transplantation (BMT) and solid organ transplantation (SOTx). The pattern of EBV related lymphoma in Chinese is different from Caucasians. We surveyed the incidence, clinical and pathological spectrum of PTLD...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290033341

    authors: Au WY,Lie AK,Kwong YL,Shek TW,Hawkins BR,Lai KN,Tang SC,Lo CM,Fan ST,Liu CL,Chan GC,Chau EM,Chiu SW,Liang R

    更新日期:2002-07-01 00:00:00

  • Chromosomal imbalances in pediatric Burkitt-like lymphoma and review of the literature in relation to other germinal center derived B-cell tumors.

    abstract::This study reports on the cytogenetic features of a novel case of pediatric Burkitt-like lymphoma (BLL), that adds to the three published. Four groups of cytogenetic abnormalities were detected in the present case: (1) imbalances shared by most germinal center (GC) derived B-cell tumors including BLL (+1q, -6q, -8p, +...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600880118

    authors: Pezzolo A,Cinti R,Negri F,Parodi F,Garaventa A,Gambini C,Pistoia V

    更新日期:2006-11-01 00:00:00

  • Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review.

    abstract::Aggressive B-cell non-Hodgkin lymphoma (aNHL) accounts for ∼50% of all NHL cases. The only potentially curative, broadly available treatment for patients with relapse, failing frontline treatment, is high-dose therapy followed by autologous stem cell transplantation (ASCT); patients ineligible for/who have failed ASCT...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1564828

    authors: Salles GA,Pettengell R,Cordoba R,Długosz-Danecka M,Jurczak W,Tilly H

    更新日期:2019-07-01 00:00:00

  • Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

    abstract::Abstract Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2012.762978

    authors: Ram R,Storb R

    更新日期:2013-08-01 00:00:00

  • The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia.

    abstract::Most human myeloid leukemias express both class I and class II HLA and it has been postulated that leukemia-associated peptides are presented by those molecules. It is possible, however, that leukemia cells escape the immune surveillance by lacking expression of "costimulatory" molecules required for activating the im...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428199909169607

    authors: Matsumoto K,Anasetti C

    更新日期:1999-11-01 00:00:00

  • Mantle cell lymphoma: state-of-the-art management and future perspective.

    abstract::Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression. Most patients present with advanced stage disease, often with extranodal dissemination, and typically pursue an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190903288514

    authors: Weigert O,Unterhalt M,Hiddemann W,Dreyling M

    更新日期:2009-12-01 00:00:00

  • Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature.

    abstract::The association of myeloproliferative and lymphoproliferative disorders is well known after cytotoxic drug or radiation exposure, while it is remarkably rare prior to therapy. We report on a patient simultaneously diagnosed as having polycythemia vera and II3A follicle center cell non-Hodgkin lymphoma (grade 1). At th...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000016113

    authors: Rizzi R,Liso A,Pannunzio A,Carluccio P,Specchia G,Liso V

    更新日期:2002-11-01 00:00:00

  • Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.

    abstract::The efficacy of All-Trans Retinoic Acid (Atra) and Arsenic Trioxide (As(2)O(3)) in the treatment of Acute Promyelocytic Leukemia (APL) is well known. Further, these drugs inhibit cell growth and induce apoptosis in several cell lines, but few data are reported on leukemic blasts. The aim of this study was to evaluate ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190400014991

    authors: Cosenza M,Civallero M,Sacchi S,Marcheselli R,Pozzi S

    更新日期:2005-02-01 00:00:00

  • Transient abnormal myelopoiesis in Down's syndrome.

    abstract::Recent data have elucidated the pathogenesis of transient abnormal myelopoiesis (TAM) to a great extent. TAM is a monoclonal disorder which resolves spontaneously and the target cell in this disorder is a multipotent stem cell which is capable of differentiating into megakaryocytes. The pathogeneses of TAM/AMKL (acute...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209051029

    authors: Kurahashi H,Hara J,Yumura-Yagi K,Tawa A,Kawa-Ha K

    更新日期:1992-12-01 00:00:00

  • Natural killer cells and the syndrome of chronic natural killer cell lymphocytosis.

    abstract::Natural killer (NK) cells provide anti-infectious, anti-neoplastic, and immunomodulatory function effected by both cytokine production and direct cellular cytotoxicity that is not major histocompatibility complex-restricted. NK cells lack truly specific cell surface determinants as well as antigen-specific receptors. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109057982

    authors: Morice WG,Leibson PJ,Tefferi A

    更新日期:2001-04-01 00:00:00